HUP9801214A2 - Lecitin-koleszterin acil-transzferázt kifejező rekombináns vírusok és génterápiában való felhasználásuk - Google Patents

Lecitin-koleszterin acil-transzferázt kifejező rekombináns vírusok és génterápiában való felhasználásuk

Info

Publication number
HUP9801214A2
HUP9801214A2 HU9801214A HUP9801214A HUP9801214A2 HU P9801214 A2 HUP9801214 A2 HU P9801214A2 HU 9801214 A HU9801214 A HU 9801214A HU P9801214 A HUP9801214 A HU P9801214A HU P9801214 A2 HUP9801214 A2 HU P9801214A2
Authority
HU
Hungary
Prior art keywords
recombinant viruses
gene therapy
cholesterol acyltransferase
viruses expressing
lecithin
Prior art date
Application number
HU9801214A
Other languages
English (en)
Inventor
Patrice Denefle
Nicolas Duverger
Martine Latta-Mahieu
Sandrine Seguret
Original Assignee
Rhone-Poulenc Rorer S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone-Poulenc Rorer S.A. filed Critical Rhone-Poulenc Rorer S.A.
Publication of HUP9801214A2 publication Critical patent/HUP9801214A2/hu
Publication of HUP9801214A3 publication Critical patent/HUP9801214A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Abstract

A találmány tárgyát őlyan hiányős rekőmbináns vírűsők képezik, amelyeka lecitin-kőleszterin acil-transzferázt (LCAT) vagy annak egy részétvagy ezek egy variánsát kódőló beépített gént tartalmaznak. Atalálmány tárgyát képezik még ezeket a vírűsőkat tartalmazógyógyszerkészítmények és alkalmazásűk diszlipőprőteinémiával kapcsőltbetegségek kezelésére vagy megelőzésére. ŕ
HU9801214A 1995-03-14 1996-03-12 Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy HUP9801214A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9502943A FR2731710B1 (fr) 1995-03-14 1995-03-14 Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique

Publications (2)

Publication Number Publication Date
HUP9801214A2 true HUP9801214A2 (hu) 1998-08-28
HUP9801214A3 HUP9801214A3 (en) 2000-08-28

Family

ID=9477007

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801214A HUP9801214A3 (en) 1995-03-14 1996-03-12 Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy

Country Status (15)

Country Link
US (1) US20010014319A1 (hu)
EP (1) EP0815239A1 (hu)
JP (1) JPH11501518A (hu)
KR (1) KR19980703008A (hu)
AU (1) AU711381B2 (hu)
BR (1) BR9607757A (hu)
CA (1) CA2214010A1 (hu)
CZ (1) CZ286897A3 (hu)
FR (1) FR2731710B1 (hu)
HU (1) HUP9801214A3 (hu)
IL (1) IL117466A0 (hu)
NO (1) NO974179L (hu)
SK (1) SK124897A3 (hu)
WO (1) WO1996028553A1 (hu)
ZA (1) ZA961998B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635614B1 (en) 1995-11-09 2003-10-21 The United States Of America As Represented By The Department Of Health And Human Services Use of lecithin-cholesterol acyltransferase (LCAT) to reduce accumulation of cholesterol
FR2755975B1 (fr) * 1996-11-15 1999-05-07 Rhone Poulenc Rorer Sa Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
ATE348171T1 (de) 1997-04-11 2007-01-15 Takeda Pharmaceutical Proteine mit lecithin-cholesterin acetyltransferase-ähnlicher aktivität, deren herstellung und verwendung
US7737861B2 (en) * 2001-06-19 2010-06-15 Paxflow Holdings Pte Ltd. Location, communication and tracking systems
ATE492630T1 (de) * 2002-06-18 2011-01-15 Eisai R&D Man Co Ltd Primäre kultivierte adipozyten zur gentherapie
CA2654608A1 (en) * 2006-06-07 2007-12-13 Reddy Us Therapeutics, Inc. Compositions and methods to enhance reverse cholesterol transport
EP2452683A3 (en) 2006-06-26 2012-08-22 Amgen Inc. Methods for treating atherosclerosis
JPWO2008108344A1 (ja) * 2007-03-02 2010-06-17 セルジェンテック株式会社 Ｌｃａｔ欠損症の遺伝子治療用細胞並びに遺伝子治療用細胞組成物
US10626414B2 (en) 2016-09-20 2020-04-21 Boehringer Ingelheim Vetmedica Gmbh Swine influenza vaccine
EP3516064A1 (en) 2016-09-20 2019-07-31 Boehringer Ingelheim Vetmedica GmbH New promoters
WO2018054837A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh New ehv insertion site orf70
CN109715219B (zh) 2016-09-20 2024-03-01 勃林格殷格翰动物保健有限公司 犬腺病毒载体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8424757D0 (en) * 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
US5049488A (en) * 1985-11-08 1991-09-17 Genentech, Inc. Method and nucleic acid for the preparation of lecithin:cholesterol acyltransferase
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
NZ269156A (en) * 1993-07-13 1996-03-26 Rhone Poulenc Rorer Sa Defective recombinant adenovirus vector incapable of replicating autonomously in a target cell and its use in gene therapy

Also Published As

Publication number Publication date
CZ286897A3 (en) 1997-12-17
IL117466A0 (en) 1996-07-23
AU5008296A (en) 1996-10-02
US20010014319A1 (en) 2001-08-16
HUP9801214A3 (en) 2000-08-28
AU711381B2 (en) 1999-10-14
WO1996028553A1 (fr) 1996-09-19
ZA961998B (en) 1996-09-26
NO974179D0 (no) 1997-09-10
FR2731710A1 (fr) 1996-09-20
BR9607757A (pt) 1999-01-26
SK124897A3 (en) 1998-02-04
NO974179L (no) 1997-09-10
KR19980703008A (ko) 1998-09-05
JPH11501518A (ja) 1999-02-09
CA2214010A1 (fr) 1996-09-19
EP0815239A1 (fr) 1998-01-07
FR2731710B1 (fr) 1997-04-30
MX9706569A (es) 1997-11-29

Similar Documents

Publication Publication Date Title
NO954466D0 (no) Adenovirale vektorer av animalsk opprinnelse samt deres anvendelse i genterapi
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
CS553490A3 (en) Transdermal therapeutic system
HUP9801214A2 (hu) Lecitin-koleszterin acil-transzferázt kifejező rekombináns vírusok és génterápiában való felhasználásuk
DE69831971D1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
BR9608449A (pt) Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica.
DE60117615D1 (de) Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen
FR2704556B1 (fr) Virus recombinants et leur utilisation en thérapie génique.
HK1019856A1 (en) Therapeutic uses of bpi protein products for human meningococcemia
ZA941426B (en) Recombinant viruses and their use in gene therapy
HUP9800635A2 (hu) In vivo exogén transzfekcióra és expresszióra használható gyógyászati kombináció
HUP9901353A2 (hu) ACE-inhibitorok alkalmazása diszpepsziás tünetek kezelésére alkalmas gyógyszerkészítmény előállítására
EP0744176A3 (en) Methods for inhibiting bone loss
HK1002284A1 (en) Novel implant and novel vector for the treatment of acquired diseases
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
ATE312179T1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
HUP9901299A2 (hu) Attenuált, nemimmunogén poxvírusokból vagy parapoxvírusokból előállított multipotens parapox immunitást előidéző gyógyszerek használatának új indikációi
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
NO964894L (no) Rekombinante viruser, deres fremstilling samt anvendelse av genterapi
SE9703287D0 (sv) Peptides
FR2778104B1 (fr) Utilisation d'un vecteur d'ions fluorure pour la preparation d'un medicament destine a la prevention ou au traitement de maladies associees a helicobacter pylori
UA9672A (uk) Спосіб лікування деструктивних форм гострого панкреатиту